Logo image of CUE

CUE BIOPHARMA INC (CUE) Stock Fundamental Analysis

USA - NASDAQ:CUE - US22978P1066 - Common Stock

0.7955 USD
-0.13 (-14.12%)
Last: 10/10/2025, 9:19:27 PM
0.7945 USD
0 (-0.13%)
After Hours: 10/10/2025, 9:19:27 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CUE. CUE was compared to 537 industry peers in the Biotechnology industry. Both the profitability and financial health of CUE have multiple concerns. While showing a medium growth rate, CUE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CUE had negative earnings in the past year.
In the past year CUE has reported a negative cash flow from operations.
CUE had negative earnings in each of the past 5 years.
CUE had a negative operating cash flow in each of the past 5 years.
CUE Yearly Net Income VS EBIT VS OCF VS FCFCUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

CUE has a worse Return On Assets (-95.55%) than 74.67% of its industry peers.
Looking at the Return On Equity, with a value of -214.19%, CUE is doing worse than 68.16% of the companies in the same industry.
Industry RankSector Rank
ROA -95.55%
ROE -214.19%
ROIC N/A
ROA(3y)-88.96%
ROA(5y)-72.96%
ROE(3y)-149.98%
ROE(5y)-114.82%
ROIC(3y)N/A
ROIC(5y)N/A
CUE Yearly ROA, ROE, ROICCUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CUE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CUE Yearly Profit, Operating, Gross MarginsCUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

2

2. Health

2.1 Basic Checks

CUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
CUE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CUE has more shares outstanding
CUE has a worse debt/assets ratio than last year.
CUE Yearly Shares OutstandingCUE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CUE Yearly Total Debt VS Total AssetsCUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

CUE has an Altman-Z score of -13.50. This is a bad value and indicates that CUE is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CUE (-13.50) is worse than 78.77% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that CUE is not too dependend on debt financing.
CUE has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: CUE outperforms 43.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -13.5
ROIC/WACCN/A
WACC9.78%
CUE Yearly LT Debt VS Equity VS FCFCUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 1.60 indicates that CUE should not have too much problems paying its short term obligations.
With a Current ratio value of 1.60, CUE is not doing good in the industry: 80.07% of the companies in the same industry are doing better.
A Quick Ratio of 1.60 indicates that CUE should not have too much problems paying its short term obligations.
CUE has a Quick ratio of 1.60. This is in the lower half of the industry: CUE underperforms 79.70% of its industry peers.
Industry RankSector Rank
Current Ratio 1.6
Quick Ratio 1.6
CUE Yearly Current Assets VS Current LiabilitesCUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

CUE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.86%, which is quite impressive.
CUE shows a decrease in Revenue. In the last year, the revenue decreased by -0.11%.
CUE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.83% yearly.
EPS 1Y (TTM)42.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55%
Revenue 1Y (TTM)-0.11%
Revenue growth 3Y-14.66%
Revenue growth 5Y21.83%
Sales Q2Q%11.14%

3.2 Future

CUE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.70% yearly.
The Revenue is expected to grow by 74.48% on average over the next years. This is a very strong growth
EPS Next Y44.11%
EPS Next 2Y20.89%
EPS Next 3Y11.71%
EPS Next 5Y32.7%
Revenue Next Year-21.59%
Revenue Next 2Y-15.91%
Revenue Next 3Y4.54%
Revenue Next 5Y74.48%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CUE Yearly Revenue VS EstimatesCUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
CUE Yearly EPS VS EstimatesCUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CUE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CUE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CUE Price Earnings VS Forward Price EarningsCUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CUE Per share dataCUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.89%
EPS Next 3Y11.71%

More info and screens

0

5. Dividend

5.1 Amount

CUE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CUE BIOPHARMA INC

NASDAQ:CUE (10/10/2025, 9:19:27 PM)

After market: 0.7945 0 (-0.13%)

0.7955

-0.13 (-14.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-06 2025-11-06/amc
Inst Owners22.62%
Inst Owner Change0%
Ins Owners0.33%
Ins Owner Change0%
Market Cap61.13M
Analysts82.86
Price Target4.08 (412.88%)
Short Float %0.87%
Short Ratio4.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)13.29%
Min EPS beat(2)-9.77%
Max EPS beat(2)36.35%
EPS beat(4)3
Avg EPS beat(4)14.16%
Min EPS beat(4)-9.77%
Max EPS beat(4)36.35%
EPS beat(8)6
Avg EPS beat(8)15.81%
EPS beat(12)9
Avg EPS beat(12)10.93%
EPS beat(16)11
Avg EPS beat(16)10.9%
Revenue beat(2)1
Avg Revenue beat(2)-22.5%
Min Revenue beat(2)-67.11%
Max Revenue beat(2)22.12%
Revenue beat(4)2
Avg Revenue beat(4)16.02%
Min Revenue beat(4)-67.11%
Max Revenue beat(4)117.33%
Revenue beat(8)6
Avg Revenue beat(8)38.37%
Revenue beat(12)8
Avg Revenue beat(12)18.85%
Revenue beat(16)10
Avg Revenue beat(16)16.5%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-9.8%
EPS NQ rev (3m)28.21%
EPS NY rev (1m)23.15%
EPS NY rev (3m)29.66%
Revenue NQ rev (1m)-21.96%
Revenue NQ rev (3m)-16.77%
Revenue NY rev (1m)-11.83%
Revenue NY rev (3m)-8.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.38
P/FCF N/A
P/OCF N/A
P/B 3.37
P/tB 3.37
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0.11
BVpS0.24
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -95.55%
ROE -214.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.96%
ROA(5y)-72.96%
ROE(3y)-149.98%
ROE(5y)-114.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.61%
Cap/Sales 2.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.6
Quick Ratio 1.6
Altman-Z -13.5
F-Score5
WACC9.78%
ROIC/WACCN/A
Cap/Depr(3y)11.7%
Cap/Depr(5y)32.79%
Cap/Sales(3y)4.77%
Cap/Sales(5y)7.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55%
EPS Next Y44.11%
EPS Next 2Y20.89%
EPS Next 3Y11.71%
EPS Next 5Y32.7%
Revenue 1Y (TTM)-0.11%
Revenue growth 3Y-14.66%
Revenue growth 5Y21.83%
Sales Q2Q%11.14%
Revenue Next Year-21.59%
Revenue Next 2Y-15.91%
Revenue Next 3Y4.54%
Revenue Next 5Y74.48%
EBIT growth 1Y18.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.07%
OCF growth 3YN/A
OCF growth 5YN/A